AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02593279 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: asthma with small airways dysfunction phenotype profile description with clinical, biological, morphologic and genetic elements.
Description: symptoms, medical history, date of start, date of aggravation, comorbidities, increased factors related to asthma, blood eosinophils, blood periostin, allergologic patch test, IgE analysis, tomodensitometric test.
Study NCT02525783 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Aequalis Pyrocarbon Humeral Head
Description: Hemi Shoulder Arthroplasty
Study NCT01171027 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: NOTES Cholecystectomy
Description: The transvaginal NOTES approach is accomplished by performing a posterior colpotomy. Instead of a conventional laparoscope, a flexible endoscope is used in order to provide working channels and visualization. The gallbladder is removed through the vaginal incision. The transgastric cholecystectomy requires the flexible endoscope to be placed orally. A gastrotomy is made through the stomach wall allowing the flexible endoscope to pass into the abdominal cavity. The gallbladder is removed from the abdominal cavity into the stomach and ultimately out the mouth. The goal of NOTES is to develop further so either of these approaches will not require any incisions in the abdominal wall.
Study NCT01171027 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: NOTES Cholecystectomy
Description: The transvaginal NOTES approach is accomplished by performing a posterior colpotomy. Instead of a conventional laparoscope, a flexible endoscope is used in order to provide working channels and visualization. The gallbladder is removed through the vaginal incision. The transgastric cholecystectomy requires the flexible endoscope to be placed orally. A gastrotomy is made through the stomach wall allowing the flexible endoscope to pass into the abdominal cavity. The gallbladder is removed from the abdominal cavity into the stomach and ultimately out the mouth. The goal of NOTES is to develop further so either of these approaches will not require any incisions in the abdominal wall.
Study NCT01171027 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic Cholecystectomy
Description: This technique utilizes the introduction of a laparoscope through a 1 cm incision in the fascia in or around umbilicus. Usually three additional 0.5- 1.0 cm incisions are employed for surgical instrumentation. Once separated from its attachments, the gallbladder is usually removed through the umbilical port. Sutures are used to close the larger port sites. The most devastating complication is injury to the major bile ducts which is avoided to the extent possible (incidence .2 to less than .01%)5 by careful visualization of the ductal structures.
Study NCT04103892 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CLE-100
Description: 1 tablet of CLE-100 administered once daily
Study NCT04103892 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 1 tablet of placebo administered once daily
Study NCT03397563 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Continuous Positive Airway Pressure
Description: standard automatic CPAP machine set on optimal automatic pressure
Study NCT03397563 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Continuous Positive Airway Pressure
Description: standard automatic CPAP machine set on optimal automatic pressure
Study NCT03397563 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: sham Continuous Positive Airway Pressure
Description: CPAP machine with pressure set below effective impact, i.e. low pressure of 4 cm H2O and adjustment of the ventilation mask
Study NCT03397563 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham Continuous Positive Airway Pressure
Description: CPAP machine with pressure set below effective impact, i.e. low pressure of 4 cm H2O and adjustment of the ventilation mask
Study NCT00384696 — intervention group
Intervention type: DRUG
Intervention: Nicotine Replacement Therapy
Description: 4 Weeks of nicotine patch. Patch therapy for participants who smoke >10 cigarettes/day consists of 2 weeks of 21 mg patches, 1 week of 14 mg patches, and 1 week of 7 mg patches. Patch therapy for participants who smoke 5-10 cigarettes/day consists of 2 weeks of 14 mg patches and 2 weeks of 7 mg patches.
Study NCT00384696 — intervention group
Intervention type: BEHAVIORAL
Intervention: Questionnaire
Description: Survey taking 1 and 1/2 hours at each study visit.
Study NCT02910310 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Uterine balloon tamponade
Description: An intervention consisting of inserting a condom attached to a urinary catheter into the uterus and inflating it with fluid to stop postpartum bleeding
Study NCT00740727 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Human recombinant hyaluronidase (HRH)
Description: 150u HRH administered via EASI access line, prior to infusion of 250 D5W (5% dextrose in water)
Study NCT00740727 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Enzymatically Augmented Subcutaneous Infusion (EASI) line placement
Description: Subjects will under placement of an EASI line. This entails placement of a small (20-gauge) catheter in the upper back, in the subcutaneous space.
Study NCT03011463 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: intravenous infusion of 2 mg trospium chloride
Description: intravenous infusion of 2 mg trospium chloride in 20 ml saline within 60 min and 240 ml tap water p.o
Study NCT03011463 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: oral administration of 30 mg trospium chloride
Description: oral administration of 30 mg trospium chloride with 240 ml tap water
Study NCT04498182 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AR-15512 Ophthalmic Solution
Description: Ophthalmic solution administered via topical ocular instillation in one of two dose concentrations: 0.0014% (lower dose) or 0.003% (higher dose)
Study NCT04498182 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: AR-15512 Ophthalmic Solution Vehicle
Description: Ophthalmic solution vehicle administered via topical ocular instillation
Study NCT02543294 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telephone Follow-Up
Description: Telephone follow-up by study staff at months 3 and 5.
Study NCT03262753 — intervention group
Intervention type: PROCEDURE
Intervention: Surgery
Description: Primary end-to-end surgical treatment of coarctation of the aorta
Study NCT03262753 — intervention group
Intervention type: PROCEDURE
Intervention: Balloon dilation
Description: Primary balloon dilation treatment of coarctation of the aorta
Study NCT03262753 — intervention group
Intervention type: PROCEDURE
Intervention: Stent
Description: Primary stent dilation treatment of coarctation of the aorta
Study NCT06381297 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: Hearing test
Description: Hearing and speech tests of MS group and control group in the presence and absence of noise will be evaluated. Suppression test will be performed with OAE test in the presence and absence of noise.
Study NCT02101892 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Amitriptyline
Description: per os, daily, evening
Study NCT02101892 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebo
Description: per os, daily, evening
Study NCT04104867 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Itopride
Description: the patients are instructed to take one pill of Itopride at 8.00 AM, 12.00 AM, 4.30 PM respectively before the dat of colonoscopy. Lastly, they are instructed to take the fourth pill at 6.00 AM on the day of colonoscopy.
Study NCT04104867 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Domperidone
Description: the patients are instructed to take one pill of Domperidone at 8.00 AM, 12.00 AM, 4.30 PM respectively before the dat of colonoscopy. Lastly, they are instructed to take the fourth pill at 6.00 AM on the day of colonoscopy.
Study NCT04104867 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: the patients are instructed to take one pill of placebo at 8.00 AM, 12.00 AM, 4.30 PM respectively before the dat of colonoscopy. Lastly, they are instructed to take the fourth pill at 6.00 AM on the day of colonoscopy.
Study NCT06381297 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Hearing test
Description: Hearing and speech tests of MS group and control group in the presence and absence of noise will be evaluated. Suppression test will be performed with OAE test in the presence and absence of noise.
Study NCT06381297 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: Speech in noise discrimination test
Description: Speech discrimination in noise (SDN) test will be performed in a quiet room in accordance with the Industrial Acoustic Company (IAC) standard using the Grason-Stadler GSI 61 Clinical Audiometer. After pure tone audiometry and speech tests, the GKAE test will be performed. The speech in noise discrimination test will be performed with a signal-to-noise (S/N) ratio of +10 dB. A word list at 50 dB SL will be presented to the tested ear using live sound, while simultaneously white noise at 40 dB SL will be presented to the test ear (Beattie et al. 1997). This will be done for both ears. The speech in noise discrimination test scores will be calculated as percentages (%) for both ears.
Study NCT01390454 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound of the elbow 1, days 7 to 15
Description: The primary endpoint is evaluated a first time via an ultrasound exam.
Study NCT01390454 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ultrasound of the elbow 1, days 7 to 15
Description: The primary endpoint is evaluated a first time via an ultrasound exam.
Study NCT01390454 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound of the elbow 2, days 7 to 15
Description: The primary endpoint is evaluated a second time by a second practitioner.
Study NCT01390454 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ultrasound of the elbow 2, days 7 to 15
Description: The primary endpoint is evaluated a second time by a second practitioner.
Study NCT01390454 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ultrasound of the elbow 3, days 45 to 90
Description: A third ultrasound is performed only on tennis elbow patients between days 45 and 90.
Study NCT01404572 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atazanavir (current formulation)
Description: Solution, oral, atazanavir 15 mg/5 mL with 10% aspartame, single dose
Study NCT01404572 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atazanavir, powder for oral use 1 (POU1)
Description: Solution, oral, atazanavir 15 mg/5 mL with 4.2% aspartame, single dose
Study NCT01404572 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atazanavir (POU2)
Description: Solution, oral, atazanavir 15 mg/5 mL with 4.2% aspartame and sucralose, single dose
Study NCT05338788 — intervention group
Intervention type: OTHER
Intervention: neck pain and dual task
Description: The Neck Disability Index (NDI) was used to assess neck pain related disability. The Biodex Balance System was used to assess postural control.Clinical test of sensory integration of balance (mCTSIB), athletic single leg test (ASLT), limits of stability (LOS), and fall risk assessment were performed with and without a cognitive task.In order to avoid the order bias of postural control measurements during Single-task and Dual-task for each case, the order of the measurements was determined by randomization on the first day by using sealed envelope method. After single/double task randomization was made, the order of tests was also randomized by using sealed envelopes containing two different orders (1-mCTSIB, 2-ASLT, 3-Fall test, 4-LOS and 1- LOS, 2- Fall test, 3- ASLT, 4-mCTSIB).
Study NCT03011463 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: oral administration of 300 mg ranitidine
Description: oral administration of 300 mg ranitidine with 240 ml tap water
Study NCT03011463 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: oral administration of 500 mg clarithromycin
Description: oral administration of 500 mg clarithromycin with 240 ml tap water
Study NCT03720184 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: HAR
Description: HAR, the 6 steps procedure that results in 300ml of haemodilution. Step 0: Circuit is primed with 1000ml of crystalloid solution. Step 1: Venous line content is drained to the reservoir. Step 2: arterial srystalloid priming is displaced to the reservoir retrogradely by autologous blood. Step 3: Crystalloid priming is discarded to the collector bag. Step 4: An amount of 300ml of arterial blood is sequestered to the reservoir avoiding the mixture. Step 5: The centrifugal pump and the oxygenator are reprimed with autologous blood displacing the priming and GME to the collector bag. Step 6: CPB is initiated with a low haemodilution of 300ml.~Available at: https://zenodo.org/record/4276132#.X7K8AchKgRk
Study NCT02938806 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study NCT02139306 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ataluren (PTC124®)
Description: Oral Ataluren TID
Study NCT02139306 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral Placebo TID
Study NCT03501550 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CDI-31244
Description: investigational drug
Study NCT03969069 — intervention group
Intervention type: DEVICE
Intervention: MAPLe
Description: Additional assessment with MAPLe
Study NCT06381297 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Speech in noise discrimination test
Description: Speech discrimination in noise (SDN) test will be performed in a quiet room in accordance with the Industrial Acoustic Company (IAC) standard using the Grason-Stadler GSI 61 Clinical Audiometer. After pure tone audiometry and speech tests, the GKAE test will be performed. The speech in noise discrimination test will be performed with a signal-to-noise (S/N) ratio of +10 dB. A word list at 50 dB SL will be presented to the tested ear using live sound, while simultaneously white noise at 40 dB SL will be presented to the test ear (Beattie et al. 1997). This will be done for both ears. The speech in noise discrimination test scores will be calculated as percentages (%) for both ears.
Study NCT06381297 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: Montreal Cognitive Assessment Scale
Description: Translated into Turkish as the Montreal Cognitive Assessment Scale and abbreviated as MOBID, MOCA assesses attention, executive/managerial functions, memory, visual-spatial skills, language, abstract thinking and arithmetic. It is easy and practical to apply. The score that can be obtained varies between 0-30. The cut-off point for cognitive impairment is 21. Patients who perform below 21 points are considered to have cognitive impairment. Although it is not a battery used in the MS patient group, a study conducted on 39 MS patients and 20 healthy people showed that it can be used safely for screening purposes in patients with MS (Aksoy et al., 2013; Nasreddine et al., 2005; Selekler \& Cangoz, 2009).
Study NCT06381297 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Montreal Cognitive Assessment Scale
Description: Translated into Turkish as the Montreal Cognitive Assessment Scale and abbreviated as MOBID, MOCA assesses attention, executive/managerial functions, memory, visual-spatial skills, language, abstract thinking and arithmetic. It is easy and practical to apply. The score that can be obtained varies between 0-30. The cut-off point for cognitive impairment is 21. Patients who perform below 21 points are considered to have cognitive impairment. Although it is not a battery used in the MS patient group, a study conducted on 39 MS patients and 20 healthy people showed that it can be used safely for screening purposes in patients with MS (Aksoy et al., 2013; Nasreddine et al., 2005; Selekler \& Cangoz, 2009).
Study NCT06381297 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: Symbol Number Modalities Test (SDMT)
Description: Attention, visuospatial information processing speed and working memory are assessed. It is one of the subtests of the Short Repeatable Neuropsychological Battery developed to assess cognitive functions in MS (Smith, 1973).
Study NCT06381297 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Symbol Number Modalities Test (SDMT)
Description: Attention, visuospatial information processing speed and working memory are assessed. It is one of the subtests of the Short Repeatable Neuropsychological Battery developed to assess cognitive functions in MS (Smith, 1973).
Study NCT05955222 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PEEK
Description: Participants receiving splints produced with CAD/CAM from PEEK blocks,
Study NCT05955222 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PMMA
Description: Participants receiving splints produced with CAD/CAM from PMMA blocks,
Study NCT05955222 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Traditional
Description: Participants receiving splints from vacuum forming system
Study NCT01124656 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pioglitazone-Azilsartan
Description: Pioglitazone-Azilsartan (30 mg + 20 mg) or (45 mg + 20 mg), tablets, orally, once daily for up to 52 weeks.
Study NCT02261922 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ticagrelor
Study NCT02261922 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: prasugrel
Study NCT01125345 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Phacoemulsification
Description: Phacoemulsification with IOL implantation in eyes undergoing bilateral cataract surgery
Study NCT01125345 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Phacoemulsification
Description: Phacoemulsification with IOL implantation in eyes undergoing bilateral cataract surgery
Study NCT03470701 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mailed Urinalysis Smartphone Kit
Description: Patients who fail to complete albuminuria screening after the initial reminder to do so, will be contacted by phone and offered a mailed smartphone urinalysis kit. Agreeable patients will then receive the mailed kit and instructions to use their smartphone camera to analyze a urine dipstick.
Study NCT03532568 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: skin biopsy
Description: 4mm punch skin biopsy
Study NCT03532568 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: narrowband ultraviolet B
Description: narrowband ultraviolet B for CKD-aP patients
Study NCT00591084 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ginsenoside-Rd 10 mg
Description: infusion ginsenoside-Rd 10 mg (group A)once a day and continued for 14 days
Study NCT00591084 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: infusion placebo (group B)once a day and continued for 14 days
Study NCT00591084 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ginsenoside-Rd 20mg
Description: infusion of ginsenoside-Rd 20mg (group C) once a day and continued for 14 days
Study NCT03101098 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Retroperitoneal liagation of uterine artery
Description: the site of ligation of uterine artery is the area that it originates from the internal iliac artery during TLH
Study NCT03101098 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Classical ligation of uterine artery
Description: the site of ligation of uterine artery is the area alongside the cervix
Study NCT04075526 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Povidone iodine
Description: To create the dilute solution, a staff member will draw up 17.5 mL of 10% povidone iodine with a syringe and mix it with 500 mL of normal saline, resulting in a dilution of 0.35% povidone iodine solution for use before wound closure.
Study NCT04075526 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vancomycin powder
Description: 2 grams of vancomycin powder will be applied to the wound and will be distributed so that approximately 1 gram is administered deep to the fascia and 1 gram superficial to the fascia
Study NCT04075526 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vancomycin powder
Description: 2 grams of vancomycin powder will be applied to the wound and will be distributed so that approximately 1 gram is administered deep to the fascia and 1 gram superficial to the fascia
Study NCT04075526 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional
Description: No additional steps in management are required for the control arm of the study besides lavage with 1 L of isotonic sodium chloride solution without antibiotics. No vancomycin powder or dilute povidone iodine lavage would be utilized in this cohort
Study NCT03501550 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SOF/VEL
Description: sofosbuvir and velpatasvir fixed dose combination
Study NCT03982056 — intervention group
Intervention type: OTHER
Intervention: this is an observational study there are no interventions
Description: development of an index to provide appropriate information on a person's ability to float, based on Physiological and anthropometric characteristics
Study NCT05028686 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: Observational cohort